Type 2 diabetes
Conditions
Interventions
Empagliflozin group: Metformin and glargine before bedtime for 12 weeks, then empagliflozin 10 mg was added for 12 weeks. FMD was measured before and after additional treatment.
Glimepiride group: M
Sponsors
Chigasaki Municipal Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Inpatients with Type 2 diabetes at Chigasaki municipal hospital 2.Patients treated with metformin and basal insulin in leaving hospital 3.Age lower limit 20, upper limit 80 4.BMI <= 45 kg/m2 5.Patients gave written consent to participate in this study
Exclusion criteria
Exclusion criteria: 1.Patients with severe renal dysfunction (eGFR < 45 ml/min/1.73m2) 2.Patients with severe liver dysfunction 3.Patients have history of cardiovascular disease and cerebral infarction within 24 weeks 4.Patients taking steroid 5.Patients with cancer 6.Patients with severe infection and trauma 7.Patients are pregnant or have possibility of pregnancy 8.Patients have an allergy to empagliflozin, glimepiride, glargine and metformin 9.Patients considered inappropriate to participate in this study by the doctor in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of FMD% with additional treatment before and after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Change of them with additional treatment before and after 12 weeks Fasting plasma glucose Postprandial plasma glucose HbA1c GA Fasting CPR Renal function Urinary albumin L-FABP UA Body weight Waist BMI Blood pressure Heart rate Lipid profile(TC, TG, HDL-C, LDL-C) Body domposition(Body fluid volume, Skeletal muscle mass, Total fat mass) 2.Adverese event | — |
Countries
Japan
Contacts
Public ContactHaruka Tamura
Chigasaki Municipal Hospital Division of Endocrinology & Metabolism
Outcome results
None listed